CR20150148A - Azaindolinas - Google Patents

Azaindolinas

Info

Publication number
CR20150148A
CR20150148A CR20150148A CR20150148A CR20150148A CR 20150148 A CR20150148 A CR 20150148A CR 20150148 A CR20150148 A CR 20150148A CR 20150148 A CR20150148 A CR 20150148A CR 20150148 A CR20150148 A CR 20150148A
Authority
CR
Costa Rica
Prior art keywords
azaindolins
compounds
cancer
formula
treatment
Prior art date
Application number
CR20150148A
Other languages
English (en)
Inventor
Joan Heather Hogg
Robert Francis Kester
Weiling Liang
Weiya Yun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20150148A publication Critical patent/CR20150148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Se divulgan compuestos de Fórmula I o sales farmacéuticamente aceptables del mismo, en el que W, Y, Z, R1, R2, R3 y R4 son como se describe en esta solicitud, y métodos para usar los compuestos en el tratamiento del cáncer.
CR20150148A 2012-10-11 2015-03-19 Azaindolinas CR20150148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712305P 2012-10-11 2012-10-11
PCT/EP2013/070881 WO2014056871A1 (en) 2012-10-11 2013-10-08 Azaindolines

Publications (1)

Publication Number Publication Date
CR20150148A true CR20150148A (es) 2015-04-30

Family

ID=49304982

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150148A CR20150148A (es) 2012-10-11 2015-03-19 Azaindolinas

Country Status (18)

Country Link
US (1) US9309248B2 (es)
EP (1) EP2906559B1 (es)
JP (1) JP6333826B2 (es)
KR (1) KR20150067182A (es)
CN (1) CN104540825B (es)
AU (1) AU2013328870A1 (es)
CA (1) CA2880324A1 (es)
CL (1) CL2015000886A1 (es)
CR (1) CR20150148A (es)
EA (1) EA201590656A1 (es)
ES (1) ES2623304T3 (es)
IL (1) IL237115A (es)
MA (1) MA38009B1 (es)
MX (1) MX2015004525A (es)
PE (1) PE20150965A1 (es)
PH (1) PH12015500399A1 (es)
SG (1) SG11201501314TA (es)
WO (1) WO2014056871A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CA3066166A1 (en) * 2017-07-06 2019-01-10 Janssen Pharmaceutica Nv New substituted azaindoline derivatives as nik inhibitors
EP4010081A4 (en) 2019-08-08 2023-07-26 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center POLYTHERAPY FOR THE TREATMENT OF CANCER
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118985A1 (en) * 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
CA2447999C (en) * 2001-05-23 2011-04-26 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
EP2457895A1 (en) 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
WO2007009883A1 (en) 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
JP2011529962A (ja) * 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
CA2747170C (en) 2008-12-19 2017-07-18 Abbott Laboratories Tetrahydroisoquinoline derivatives and their uses to treat cancers and autoimmune disorders
JP5529282B2 (ja) * 2009-10-28 2014-06-25 ジョイアント ファーマスーティカルズ、インク． 二量体Ｓｍａｃ模倣薬
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CA2879870A1 (en) * 2012-10-11 2014-04-17 F. Hoffmann-La Roche Ag Azaindolines

Also Published As

Publication number Publication date
EP2906559A1 (en) 2015-08-19
PE20150965A1 (es) 2015-06-20
WO2014056871A1 (en) 2014-04-17
CN104540825A (zh) 2015-04-22
CA2880324A1 (en) 2014-04-17
PH12015500399A1 (en) 2015-04-27
US20150266879A1 (en) 2015-09-24
US9309248B2 (en) 2016-04-12
ES2623304T3 (es) 2017-07-10
SG11201501314TA (en) 2015-03-30
EP2906559B1 (en) 2017-02-08
MA38009B1 (fr) 2018-09-28
HK1206738A1 (en) 2016-01-15
JP6333826B2 (ja) 2018-05-30
AU2013328870A1 (en) 2015-02-26
KR20150067182A (ko) 2015-06-17
JP2015534570A (ja) 2015-12-03
CN104540825B (zh) 2017-10-24
MA38009A1 (fr) 2018-02-28
CL2015000886A1 (es) 2015-07-17
EA201590656A1 (ru) 2015-07-30
IL237115A (en) 2016-12-29
MX2015004525A (es) 2015-07-06

Similar Documents

Publication Publication Date Title
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CR20150211A (es) Compuestos diméricos
UY33883A (es) Novedosos derivados heterocíclicos
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
MX2016007585A (es) Inhibidores de desmetilasa-1 especifica de lisina.
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
PE20151023A1 (es) Triazolopirazinas
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
CR20140367A (es) Inhibidores de iap
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
MX2018004664A (es) Antagonistas de ep4.
CR20150148A (es) Azaindolinas
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.